Caspian Journal of Internal Medicine
Babol University of Medical Sciences
Sat, May 31, 2025
[Archive]
Volume 13, Issue 4 (Autumn 2022)
Caspian J Intern Med 2022, 13(4): 800-804 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ala S, Saeedi M, Ghasemi A, Namdari M, Koulaeinejad N. Effect of atorvastatin 1% mouthwash in the prevention of radiotherapy induced mucositis: A pilot study. Caspian J Intern Med 2022; 13 (4) :800-804
URL: http://caspjim.com/article-1-2805-en.html
URL: http://caspjim.com/article-1-2805-en.html
Department of radiology and radiation oncology, Faculty of medicine, Mazandaran University of medical science, Sari, Iran , dr_arash_ghasemi@yahoo.com
Abstract: (3285 Views)
Background: Oral mucositis is a troublesome symptom for people who receive radiotherapy and chemotherapy and it is a dose-dependent factor. Atorvastatin is a HMG-CoA reductase inhibitors and various studies have proven its anti-inflammatory effects. The goal of this study was to evaluate atorvastatin 1% mouthwash effects in prevention of radiotherapy-induced mucositis.
Methods: Atorvastatin 1% suspension was prepared for mouthwash in this randomized, double-blind clinical trial. Thirty patients randomly received atorvastatin or placebo mouthwash. They had to gargle 5cc of mouthwash, 3 times per day during radiotherapy. The severity and pain of mucositis was evaluated every week, during their treatment.
Results: The severity of mucositis between the two study groups was significant every four weeks (p<0.05) and the percentage of patients with more severe mucositis was less in the atorvastatin group. It is found that the pain intensity was lower after 3 and 4 weeks in atorvastatin group.
Conclusion: These findings indicated that atorvastatin mouthwash showed a significant activity in relieving of radiotherapy-induced oral mucositis and pain.
Methods: Atorvastatin 1% suspension was prepared for mouthwash in this randomized, double-blind clinical trial. Thirty patients randomly received atorvastatin or placebo mouthwash. They had to gargle 5cc of mouthwash, 3 times per day during radiotherapy. The severity and pain of mucositis was evaluated every week, during their treatment.
Results: The severity of mucositis between the two study groups was significant every four weeks (p<0.05) and the percentage of patients with more severe mucositis was less in the atorvastatin group. It is found that the pain intensity was lower after 3 and 4 weeks in atorvastatin group.
Conclusion: These findings indicated that atorvastatin mouthwash showed a significant activity in relieving of radiotherapy-induced oral mucositis and pain.
Type of Study: Short Communication |
Subject:
Oncology
Received: 2021/03/13 | Accepted: 2021/09/18 | Published: 2022/09/15
Received: 2021/03/13 | Accepted: 2021/09/18 | Published: 2022/09/15
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
